Adalimumab efficacy is inversely correlated with body mass index ( BMI ) in hidradenitis suppurativa
International Journal of Dermatology · 2023-06 · 62 (6) · 764-769
DOI: 10.1111/ijd.16565 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Dermatology, online erschienen am 29.12.2022. Verfasst von Avigdor Nosrati und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Adalimumab is the only FDA‐approved biologic for hidradenitis suppurativa (HS). In the setting of increasing obesity rates worldwide, the relationship between adalimumab efficacy for HS and BMI is essential to understand. We assessed this relationship through markers of disease severity and inflammation.
Methods
Institutional review board‐approved retrospective chart review of Montefiore/Einstein HS Center (HSC) patients ( n = 57) treated with adalimumab. The relationship between BMI and adalimumab efficacy was assessed through disease severity (HS‐Physician Global Assessment [HS‐PGA] 0 and Numerical Rating Scale Pain [NRS‐Pain]) and inflammatory markers (erythrocyte sedimentation rate [ESR], C‐reactive protein [CRP], and interleukin‐6 [IL‐6]). A BMI ≥ 30 is defined as obese; BMI < 30 is defined as non‐obese.
Results
The mean age was 35.8 ± 13.0 years. After adalimumab therapy, those with BMI < 30 experienced significant reductions in HS‐PGA (−1.5 ± 0.9; P < 0.0001) and NRS‐Pain (−1.6 ± 2.1; P < 0.0001), as well as mean decreases in inflammatory markers ESR, CRP, and IL‐6 (−17.90 ± 23.6, −0.71 ± 1.4, −5.88 ± 7.9, respectively; P > 0.05). Obese patients (BMI ≥ 30) experienced mean increases in HS‐PGA (+0.22 ± 0.8; P > 0.05) and NRS‐Pain scores (+1.41 ± 3.5; P > 0.05) as well as mean increases in ESR, CRP, and IL‐6 (+2.62 ± 28.3, +0.44 ± 3.0, +2.35 ± 6.9, respectively; P > 0.05). Comparing the cohorts, differences in changes in HS‐PGA, NRS‐Pain, ESR, and IL‐6 after therapy are significantly different ( P < 0.05).
Conclusions
We identified significantly lower efficacy of adalimumab in HS patients with BMI ≥ 30 compared to those with BMI < 30. Those with BMI ≥ 30 demonstrated signs of both clinical and physiological deterioration while on adalimumab. Future studies are needed to examine adalimumab dosing for HS patients with high BMI, as well as a critical reconsideration of weight‐based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, New York, NY, USA.
ORCID-Profile: Avigdor Nosrati, McCall E Torpey, Peter Y Ch'en, Tyler M Andriano, Gabrielle Benesh, H Dean Hosgood, Steven R Cohen
Zitieren
APA
Nosrati, A., Torpey, M. E., Shokrian, N., Ch'en, P. Y., Andriano, T. M., Benesh, G., Heibel, H. D., Hosgood, H. D., Campton, K. L., & Cohen, S. R. (2023). Adalimumab efficacy is inversely correlated with body mass index ( BMI ) in hidradenitis suppurativa. International Journal of Dermatology, 62(6), 764-769. https://doi.org/10.1111/ijd.16565
Vancouver
Nosrati A, Torpey ME, Shokrian N, Ch'en PY, Andriano TM, Benesh G, et al. Adalimumab efficacy is inversely correlated with body mass index ( BMI ) in hidradenitis suppurativa. International Journal of Dermatology. 2023;62(6):764-769. doi:10.1111/ijd.16565
BibTeX
@article{Nosrati2023,
author = {Nosrati, Avigdor and Torpey, McCall E and Shokrian, Neda and Ch'en, Peter Y and Andriano, Tyler M and Benesh, Gabrielle and Heibel, Haley D and Hosgood, H Dean and Campton, Kristina L and Cohen, Steven R},
title = {Adalimumab efficacy is inversely correlated with body mass index ( BMI ) in hidradenitis suppurativa},
journal = {International Journal of Dermatology},
year = {2023},
volume = {62},
number = {6},
pages = {764--769},
doi = {10.1111/ijd.16565}
}
EUVIMED